All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-04-03T09:18:15.000Z

International T-cell Project: a subgroup analysis of patients with extranodal natural killer T-cell lymphoma

Apr 3, 2020
Share:

Bookmark this article

Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a rare and aggressive disease. Radiotherapy is effective in early-stage disease1, but most patients with advanced stage or extranasal disease have poor outcomes. This aggressive lymphoma is resistant to anthracycline-based chemotherapy2, and recent studies support the treatment with non-anthracycline-based chemoradiotherapy for localized disease3, and incorporating L-asparaginase into non-anthracycline -based regimens for advanced-stage and relapsed or refractory ENKTL.4-5

A recent study, published by Christopher Fox et al. in Lancet Haematology, analyzed data on a cohort of patients with ENKTL from the T-cell Project (NCT01142674), exploring the clinical characteristics and outcomes of patients with ENKTL.6

Study design and patient characteristics

  • Of the 1,695 patients, aged > 18 years old with mature T-cell or NK lymphomas, registered in the T-Cell Project cohort6
    • 1,553 were eligible for analysis
    • Of these, 166 patients were diagnosed with ENKTL
      • nasal-type, n = 98
      • extranasal-type, n = 68
  • According to the prognostic index of NK lymphoma (PINK),7 considering four risk factors (age ˃ 60 years, stage III or IV, distant lymph-node involvement, non-nasal type disease), patients were stratified as low (0 factors), intermediate (1 factor), and high risk (2 factors)
  • Primary outcome: 5-year overall survival (OS)
  • Secondary endpoints:
    • 5-year progression free survival (PFS)
    • 3-year OS and PFS
  • In the entire population, median age was 53 years, the majority of patients were male (65%) and had received first-line treatment of chemo alone (33%), radiotherapy alone (4%), combination of chemotherapy and radiotherapy (56%), or chemotherapy and consolidation high-dose treatment (11%)
  • Patients with extranasal disease had more adverse clinical conditions than those with nasal disease such as, involvement of ˃ 1 extranodal site, and high serum lactate dehydrogenase

Results6

OS and PFS were estimated after a median follow-up of 44 months (IQR 20–61) and data are reported in Table 1.

  • In patients with stage I-II vs patients with stage III-IV ENKTL:  median PFS, 46 months (11–81) vs 15 months (9–20; HR 7.2, 95% CI, 5.4–19.9; p = 0.021), and median OS 59 months (not estimable–not estimable) vs 19 months (4–34; p = 0.042), respectively
Table 1. OS and PFS in the overall cohort and by ENKTL subtype
CI, confidence interval; HR, hazard ratio; PFS, progression free survival; OS, overall survival

 

 

Parameter

Total ENKTL cohort

Nasal type

Extranasal type

Stage I

Stage II

Stage III–IV

Median OS,

months

59

(95% CI, 41–86)

not reached

18

not reached

29

10

HR 9.6 (95% CI, 9.2–32.4); p = 0.019

HR 3.1 (95% CI, 1–62);

p = 0.067

vs stage I, HR 2.9 (95% CI, 2.4–16.1)

Median PFS,

months

20

(95% CI,

1–39)

39

14

not reached

13

8

HR 5.7 (95% CI, 5.1–28.9); p = 0.042

HR 3.2 (95% CI, 0–21);

p = 0.012

vs stage I, HR 2.7 (95% CI, 2.1–14.2)

3-year OS, %

 

63

44

69

48

33

3-year PFS, %

 

51

39

 

 

 

5-year OS, %

 

54

34

55

42

24

5-year PFS, %

 

47

26

 

 

 

Based on PINK score, patients (n = 144 with available data) were classified as:

  • Low-risk (n = 34)
  • intermediate-risk (n = 41)
  • high-risk (n = 69)

In low-risk vs intermediate-risk vs high-risk:

  • 5-year OS 54% vs 51% vs 35% (p = 0.0021)
  • 5- year PFS 56% vs 34% vs 28% (p = 0.0082)

Outcomes based on treatment were evaluated in 130 patients (75 nasal disease, 55 extranasal) and data are reported in Table 2. The most used regimen incorporating L-asparaginase was the SMILE protocol (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide), administered in 23 patients.

Table 2. Patient outcomes based on treatment

PFS, progression free survival; OS, overall survival

 

 

 

Parameter

Stage I–II

Stage III–IV

Chemotherapy

(n = 11)

Chemotherapy plus radiotherapy

(n = 48)

Chemotherapy

(n = 27)

Chemotherapy plus radiotherapy

(n = 27)

3-year OS, %

12

70

24

66

3-year PFS, %

0

66

14

59

5-year OS, %

12

59

24

58

5-year PFS, %

0

53

0

40

Relative to the chemotherapeutic regimen used, outcomes in patients receiving L-asparaginase based regimen vs those receiving an anthracycline-based regimen vs those not receiving either drug, were:

  • 5-year PFS: 42% vs 26% vs 59%
  • 5-year OS: 50% vs 31% vs 66%

Of 130 patients, 93 responded to first-line therapy:

  • Complete response (CR): 84 (nasal disease, 54; extranasal disease, 30)
  • Partial response (PR): 9 (nasal disease, two; extranasal disease, seven)

In patients achieving CR, 5-year OS was 63% and 5-year PFS was 61%. In patients achieving only PR, 5-year OS was 32% and 5-year PFS was not estimable.

CR was also evaluated by treatment group:

  • In patients with stage I–II disease (n = 60), CR in chemotherapy alone vs radiotherapy alone vs chemotherapy plus radiotherapy, was 13% vs 25% vs 79%, respectively
  • In patients with stage III–IV disease (n = 60), treated with L-asparaginase-based vs anthracycline-based vs non- anthracycline /non-asparaginase protocols, was 67% vs 30% vs 1%, respectively

Conclusions6

  • The T-cell project is a global study involving 74 hospitals in 13 countries. Results from this subgroup analysis highlighted the importance of using radiation therapy together with chemotherapy in the management of ENKTL with an improved OS and PFS in patients treated with this combined therapy
  • Patients with advanced stage disease, treated with L-asparaginase-based regimen showed a better response compared to patients treated with anthracycline-based or non- anthracycline /non-asparaginase regimens
  • Patients with extranasal disease, high-risk PINK score had poor prognosis and investigational therapies are warranted

  1. Li Y.X. et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006 Jan 1; 24(1):181– DOI: 10.1200/JCO.2005.03.2573
  2. Kim B.S. et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. Acta Oncol. 2003; 42(7):779– DOI: 10.1080/02841860310010682
  3. Yamaguchi M. et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009 Nov 20; 27(33):5594– DOI: 10.1200/JCO.2009.23.8295

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox